Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-04-23 AGM Information
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
THERAVET - AGO 2024 - PV - final.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "PROCES-VERBAL DE L'ASSEMBLEE GENERALE ORDINAIRE DES ACTIONNAIRES DU 6 JUIN 2024" (Minutes of the Ordinary General Meeting of Shareholders of June 6, 2024). This document details the proceedings, attendance, agenda items (including approval of annual accounts and discharge of directors), and the voting results of a shareholder meeting. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it contains elements related to the Annual Report (approval of accounts for FY 2023), the primary nature and title of the document is the official record of the AGM itself.
2024-04-23 French
THERAVET - AGO 2024 - Procuration - Natural Persons.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled "Procuration d'actionnaire (Personnes Physiques)" / "Shareholder proxy (Natural Persons)". It explicitly details the process for a shareholder to designate a proxy holder to represent them at the "assemblée générale ordinaire" (ordinary general meeting). The agenda items (Points 1-7) cover the approval of annual reports, annual accounts, discharge to directors/auditor, and confirmation/renewal of director mandates, which are standard items for an Annual General Meeting (AGM). The document itself is a proxy form used to facilitate voting at the AGM, not the final voting results (DVA) or the AGM presentation materials (AGM-R). Since it is directly related to the mechanism of voting at the AGM, it falls under the scope of materials related to the meeting, which is best classified as AGM-R, as it is a core component of the AGM process for shareholders who cannot attend in person. It is not a DEF 14A (Remuneration) or a PSI (Proxy Solicitation), as it is the actual form to appoint a proxy, rather than the solicitation document itself.
2024-04-23 French
THERAVET - AGO 2024 - Procuration - Legal Entities.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Shareholder proxy (Legal Entities)' and contains a 'Shareholder proxy' form ('Procuration d'actionnaire'). It explicitly details the process for shareholders to designate a proxy holder to represent them at the 'assemblée générale ordinaire' (ordinary general meeting). The agenda items (Ordre du jour) confirm the purpose, including deliberation on the annual report and accounts, discharge to directors, and renewal of director mandates, which are typical items for an AGM. The document itself is the proxy form used to vote or appoint representation for the AGM, making it directly related to the Annual General Meeting process. This aligns best with the AGM Information (AGM-R) category, which covers presentations and materials shared during the AGM, and the proxy form is a key material for participation.
2024-04-23 French
THERAVET - AGO 2024 - Convocation.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Convocation à l'assemblée générale ordinaire' (Notice of Annual General Meeting) for TheraVet SA. It outlines the agenda, voting procedures, and logistical details for the upcoming meeting on June 6, 2024. In the context of financial filings, documents that solicit votes and provide information for an upcoming shareholder meeting are classified as Proxy Solicitation & Information Statements.
2024-04-23 French
THERAVET - AGO 2024 - Convening notice.pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'CONVENING LETTER TO THE ORDINARY GENERAL MEETING OF SHAREHOLDERS OF 6 JUNE 2024'. It details the agenda for this meeting, which includes deliberation on the annual report, approval of annual accounts, discharge to directors, and renewal of director terms. These elements are characteristic of materials sent out to shareholders in advance of an Annual General Meeting (AGM). While it discusses the annual report (related to 10-K/AR), the document's primary function is to convene the meeting and solicit votes, making 'AGM Information' (AGM-R) the most appropriate classification.
2024-04-23 English
THERAVET - Rapport de gestion_2024.pdf
AGM Information Classification · 98% confidence The document is titled "Rapport de gestion en vue de l'assemblée générale ordinaire du 06 Juin 2024" (Management report for the Ordinary General Meeting of June 06, 2024). It covers the financial year 2023, discusses the financial results, significant post-closing events, R&D activities, going concern assessment, and explicitly asks for discharge for administrators and the external accountant, which are typical components of a management report presented at an AGM. While it relates to the AGM, the core content is the comprehensive annual management discussion and analysis of the financial year, which aligns closely with the scope of an Annual Report (10-K) or a detailed management report accompanying annual accounts. Given the context of a detailed report covering the full fiscal year (2023) including financial performance, management discussion, and going concern assessment, it is best classified as a comprehensive annual report/management report. Since the definitions separate 10-K (Official yearly report) from AR (Standalone audit reports) and IR (Interim reports), and this document is a 'Rapport de gestion' for the full year, it strongly suggests the comprehensive annual reporting package. However, since it is explicitly framed for the AGM and contains management discussion, it fits the spirit of a comprehensive annual filing. In many jurisdictions, the 'Rapport de gestion' is the primary component of the annual filing package. Given the detailed financial review and the context of the upcoming AGM, it is most analogous to the comprehensive annual reporting requirements, which maps best to the '10-K' category for full-year reporting, or potentially 'AR' if it were strictly the auditor's opinion, but it is clearly a management report. Since it is a full-year management report presented for approval at the AGM, '10-K' is the closest fit for a comprehensive annual review, although 'AR' (Audit Report/Information) is also plausible if the focus is on the statutory reporting aspect. Given the length and depth, and the reference to the full fiscal year 2023, I will classify it as 10-K, representing the comprehensive annual report/management discussion.
2024-04-23 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.